How Phosphofructokinase-1 Promotes PI3K and YAP/TAZ in Cancer: Therapeutic Perspectives.

Simula, Luca; Alifano, Marco; Icard, Philippe

Simula, Luca; Alifano, Marco; Icard, Philippe.

Afiliación

Simula L; Department of Infection, Immunity and Inflammation, Cochin Institute, INSERM U1016, CNRS UMR8104, University of Paris, 75014 Paris, France.
Alifano M; INSERM U1138, Integrative Cancer Immunology, University of Paris, 75006 Paris, France.
Icard P; Service de Chirurgie Thoracique, Hôpital Cochin, Hôpitaux Universitaires Paris Centre, APHP, Paris-Descartes University, 75014 Paris, France.

Cancers (Basel) ; 14(10)2022 May 18.

Article en En | MEDLINE | ID: mdl-35626081

Palabras clave

F-1,6-BP; PFK1; PI3K; YAP/TAZ; citrate; drug resistance

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Francia